Pharma Report: New drugs coming, but what about Pfizer?

Investors have long heard of the problems plaguing Big Pharma, especially blockbuster drugs coming off patent in the near future, exposing them to competition from cheaper generics. A record number of drug sales will come off patent in the upcoming "patent cliff" arriving in 2010-2012. BusinessWeek lists a few: Pfizer's (PFE) Lipitor, Bristol-Myers Squibb's (BMY) Plavix and Avapro, Eli Lilly's (LLY) Zyprexa, Wyeth's (WYE) Effexor, and Merck's (MRK) Cozaar/Hyzaar and Singulair.

But there are some promising drugs to replace the lost sales of these blockbusters, according to Arthur Wong of S&P: